Korro Bio (KRRO) Free Cash Flow (2018 - 2026)
Korro Bio's (KRRO) quarterly Free Cash Flow came in at -$16.1 million in Q1 2026, up 34.5% YoY from -$12.0 million in Q1 2025, and up 9.51% on a QoQ basis from -$17.8 million in Q4 2025.
Korro Bio (KRRO) Free Cash Flow (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Free Cash Flow data on file, last reported at -$16.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 34.5% year-over-year to -$16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.6 million (up 5.92% YoY) and the FY2025 annual result came in at -$79.1 million, down 1.41% from the prior year.
- Free Cash Flow advanced to -$16.1 million in Q1 2026, from -$17.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$8.9 million in Q4 2024 to a low of -$27.5 million in Q1 2024.
- A 5-year average of -$18.1 million and a median of -$17.8 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 60.69% — and 2025, when it sank 98.79%.
- Tracing KRRO's Free Cash Flow over 5 years: stood at -$16.2 million in 2022, then tumbled by 40.83% to -$22.8 million in 2023, then jumped by 60.69% to -$8.9 million in 2024, then slumped by 98.79% to -$17.8 million in 2025, then gained by 9.51% to -$16.1 million in 2026.
- The last three Free Cash Flow figures came in at -$16.1 million (Q1 2026), -$17.8 million (Q4 2025), and -$17.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -17.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.03 Mn |
| Jun 30, 2026 | -17.03 Mn |
| Mar 31, 2026 | -16.10 Mn |
| Mar 31, 2026 | -16.10 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Sep 30, 2025 | -17.35 Mn |
| Sep 30, 2025 | -17.35 Mn |
| Jun 30, 2025 | -19.37 Mn |
| Jun 30, 2025 | -19.37 Mn |
| Mar 31, 2025 | -24.57 Mn |
| Mar 31, 2025 | -24.57 Mn |
| Dec 31, 2024 | -8.95 Mn |
| Dec 31, 2024 | -8.95 Mn |
| Sep 30, 2024 | -20.97 Mn |
| Sep 30, 2024 | -20.97 Mn |
| Jun 30, 2024 | -20.55 Mn |
| Jun 30, 2024 | -20.55 Mn |
| Mar 31, 2024 | -27.50 Mn |
| Mar 31, 2024 | -27.50 Mn |